The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Triple-negative breast cancer—current status and future directions
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“However, since the introduction of trastuzumab as a potent therapeutic approach in HER-2positive BC, HER-2 expression is perceived as a favorable predictive rather than negative prognostic factor [4–6].”
BackgroundSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 2×
“The aggressiveness of TNBC is further indicated by the fact that (i) the peak risk of recurrence occurs within the first 3 years after initial treatment of the disease with the majority of deaths occurring in the first 5 years [18, 42] and (ii) after diagnosis of metastatic disease, a significantly shorter survival wa…”
BackgroundTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Self-citationSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Self-citationNielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,067
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj052 · Cited by 2,063
Generation of a functional mammary gland from a single stem cell
Shackleton, M., Vaillant, F., Simpson, K. J., Stingl, J., Smyth, G. K., Asselin-Labat, M.-L., Wu, L., Lindeman, G. J., & Visvader, J. E. (2006) · Nature · doi:10.1038/nature04372 · Cited by 2,005
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Self-citationMeasurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Self-citationCitron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Prognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O. (2007) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,283
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Haffty, B. G., Yang, Q., Reiss, M., Kearney, T., Higgins, S. A., Weidhaas, J., Harris, L., Hait, W., & Toppmeyer, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5664 · Cited by 1,084
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype
Sarrió, D., Rodriguez-Pinilla, S. M., Hardisson, D., Cano, A., Moreno-Bueno, G., & Palacios, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2017 · Cited by 1,056
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707056 · Cited by 997
Ogston, K. N., Miller, I. D., Payne, S., Hutcheon, A. W., Sarkar, T. K., Smith, I., Schofield, A., & Heys, S. D. (2003) · The Breast · doi:10.1016/s0960-9776(03)00106-1 · Cited by 982
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm271 · Cited by 944
Epidemiology of basal-like breast cancer
Millikan, R. C., Newman, B., Tse, C.-K., Moorman, P. G., Conway, K., Smith, L. V., Labbok, M. H., Geradts, J., Bensen, J. T., Jackson, S., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9632-6 · Cited by 886
Triple-negative breast cancer: therapeutic options
Cleator, S., Heller, W., & Coombes, R. C. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70074-8 · Cited by 882
Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Harris, A., Bergh, J., Foekens, J. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1522 · Cited by 837
Lakhani, S. R., van de Vijver, M. J., Jacquemier, J., Anderson, T. J., Osin, P. P., McGuffog, L., & Easton, D. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.023 · Cited by 823
Nguyen, P. L., Taghian, A. G., Katz, M. S., Niemierko, A., Abi Raad, R. F., Boon, W. L., Bellon, J. R., Wong, J. S., Smith, B. L., & Harris, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4287 · Cited by 811
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study
Kuhl, C. K., Schrading, S., Bieling, H. B., Wardelmann, E., Leutner, C. C., Koenig, R., Kuhn, W., & Schild, H. H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61232-x · Cited by 711
Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., Bishop, T., Benitez, J., Rivas, C., Bignon, Y.-J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2424 · Cited by 611
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071167 · Cited by 608
Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O. (2005) · International Journal of Cancer · doi:10.1002/ijc.21004 · Cited by 606
Morris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P., Schwartz, G. F., Park, P. K., Rosenberg, A. L., Brill, K., et al. (2007) · Cancer · doi:10.1002/cncr.22836 · Cited by 602
BRCA1 dysfunction in sporadic basal-like breast cancer
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210014 · Cited by 573
Kyndi, M., Sørensen, F. B., Knudsen, H., Overgaard, M., Nielsen, H. M., & Overgaard, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5565 · Cited by 568
Pattern of metastatic spread in triple-negative breast cancer
Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0086-2 · Cited by 554
The CD44+/CD24-phenotype is enriched in basal-like breast tumors
Honeth, G., Bendahl, P.-O., Ringnér, M., Saal, L. H., Gruvberger-Saal, S. K., Lövgren, K., Grabau, D., Fernö, M., Borg, Å., & Hegardt, C. (2008) · Breast Cancer Research · doi:10.1186/bcr2108 · Cited by 551
Hugh, J., Hanson, J., Cheang, M. C. U., Nielsen, T. O., Perou, C. M., Dumontet, C., Reed, J., Krajewska, M., Treilleux, I., Rupin, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1024 · Cited by 526
Bergamaschi, A., Kim, Y. H., Wang, P., Sørlie, T., Hernandez‐Boussard, T., Lonning, P. E., Tibshirani, R., Børresen‐Dale, A., & Pollack, J. R. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20366 · Cited by 506
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489
Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study
Yang, X. R., Sherman, M. E., Rimm, D. L., Lissowska, J., Brinton, L. A., Peplonska, B., Hewitt, S. M., Anderson, W. F., Szeszenia-Dąbrowska, N., Bardin-Mikolajczak, A., et al. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0806 · Cited by 464
Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 463
How basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
Glass, A. G., Lacey, J. V., Carreon, J. D., & Hoover, R. N. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm059 · Cited by 439
The Role of BRCA1 in the Cellular Response to Chemotherapy
Kennedy, R. D., Quinn, J. E., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh312 · Cited by 430
Finn, R. S., Dering, J., Ginther, C., Wilson, C. A., Glaspy, P., Tchekmedyian, N., & Slamon, D. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9463-x · Cited by 409
Gennari, A., Sormani, M. P., Pronzato, P., Puntoni, M., Colozza, M., Pfeffer, U., & Bruzzi, P. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm252 · Cited by 371
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Tischkowitz, M., Brunet, J.-S., Bégin, L. R., Huntsman, D. G., Cheang, M. C., Akslen, L. A., Nielsen, T. O., & Foulkes, W. D. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-134 · Cited by 365
Foulkes, W. D., Brunet, J.-S., Stefansson, I. M., Straume, O., Chappuis, P. O., Bégin, L. R., Hamel, N., Goffin, J. R., Wong, N., Trudel, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2970 · Cited by 363
Tirkkonen, M., Johannsson, O. T., Agnarsson, B. A., Olsson, H. L., Ingvarsson, S., Karhu, R., Tanner, M., Isola, J. J., Barkardottir, R. B., Borg, Å., et al. (1997) · PubMed · Cited by 354
Fulford, L. G., Easton, D. F., Reis‐Filho, J. S., Sofronis, A., Gillett, C. E., Lakhani, S. R., & Hanby, A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02453.x · Cited by 352
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344 · cited 1×
“In vitro evidence supports the use of this small molecule particularly in subgroup of BLBC in which several tyrosine kinase receptors such as stem-cell factor receptor (c-kit) are overexpressed and/or mutated [155, 156].”
BackgroundTriple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings
Uematsu, T., Kasami, M., & Yuen, S. (2009) · Radiology · doi:10.1148/radiol.2503081054 · Cited by 344
Metaplastic breast carcinomas are basal‐like tumours
Reis‐Filho, J. S., Milanezi, F., Steele, D., Savage, K., Simpson, P. T., Nesland, J. M., Pereira, E. M., Lakhani, S. R., & Schmitt, F. C. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02467.x · Cited by 341
The epidemiology of triple-negative breast cancer, including race
Trivers, K. F., Lund, M. J., Porter, P. L., Liff, J. M., Flagg, E. W., Coates, R. J., & Eley, J. W. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9331-1 · Cited by 332
Rodríguez-Pinilla, S. M., Sarrió, D., Honrado, E., Hardisson, D., Calero, F., Benitez, J., & Palacios, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2281 · Cited by 324
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
Kwan, M. L., Kushi, L. H., Weltzien, E., Maring, B., Kutner, S. E., Fulton, R. S., Lee, M. M., Ambrosone, C. B., & Caan, B. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2261 · Cited by 318
Tan, D. S. P., Marchió, C., Jones, R. L., Savage, K., Smith, I. E., Dowsett, M., & Reis-Filho, J. S. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9756-8 · Cited by 318
Caldas-Lopes, E., Cerchietti, L., Ahn, J. H., Clement, C. C., Robles, A. I., Rodina, A., Moulick, K., Taldone, T., Gozman, A., Guo, Y., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903392106 · Cited by 315
Millar, E. K. A., Graham, P. H., O'Toole, S. A., McNeil, C. M., Browne, L., Morey, A. L., Eggleton, S., Beretov, J., Theocharous, C., Capp, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7075 · Cited by 314
Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 304
Integrated Profiling of Basal and Luminal Breast Cancers
Adélaïde, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., Charafe-Jauffret, E., Cervera, N., Desplans, J., Parzy, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2536 · Cited by 297
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
Banerjee, S., Reis-Filho, J. S., Ashley, S., Steele, D., Ashworth, A., Lakhani, S. R., & Smith, I. E. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.033043 · Cited by 290
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
Young, Sr., Pilarski, R. T., Donenberg, T., Shapiro, C., Hammond, L. S., Miller, J., Brooks, K. A., Cohen, S., Tenenholz, B., DeSai, D., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-86 · Cited by 273
Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years
Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L., & Malone, K. E. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-1005 · Cited by 271
Leong, C.-O., Vidnovic, N., DeYoung, M. P., Sgroi, D., & Ellisen, L. W. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30866 · Cited by 270
Triple-negative breast cancers are increased in black women regardless of age or body mass index
Stead, L. A., Lash, T. L., Sobieraj, J. E., Chi, D. D., Westrup, J. L., Charlot, M., Blanchard, R. A., Lee, J. C., King, T. C., & Rosenberg, C. L. (2009) · Breast Cancer Research · doi:10.1186/bcr2242 · Cited by 250
Basu, S., Chen, W., Tchou, J., Mavi, A., Cermik, T., Czerniecki, B., Schnall, M., & Alavi, A. (2008) · Cancer · doi:10.1002/cncr.23226 · Cited by 248
O'Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B., & Bradley, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3 · Cited by 242
Korsching, E., Packeisen, J., Agelopoulos, K., Eisenacher, M., Voss, R., Isola, J., van Diest, P. J., Brandt, B., Boecker, W., & Buerger, H. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000038508.86221.b3 · Cited by 238
Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis
Weigelt, B., Kreike, B., & Reis-Filho, J. S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0197-9 · Cited by 224
The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles
Glenney, J. R. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)81458-x · Cited by 221
Platinum-based chemotherapy in triple-negative breast cancer
Sirohi, B., Arnedos, M., Popat, S., Ashley, S., Nerurkar, A., Walsh, G., Johnston, S., & Smith, I. E. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn395 · Cited by 220
Can Women With Early-Stage Breast Cancer Make an Informed Decision for Mastectomy?
Collins, E. D., Moore, C. P., Clay, K. F., Kearing, S. A., O'Connor, A. M., Llewellyn-Thomas, H. A., Barth, R. J., & Sepucha, K. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6215 · Cited by 220
Collett, K., Stefansson, I. M., Eide, J., Braaten, A., Wang, H., Eide, G. E., Thoresen, S. Ø., Foulkes, W. D., & Akslen, L. A. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0394 · Cited by 215
Brown, M., Tsodikov, A., Bauer, K. R., Parise, C. A., & Caggiano, V. (2008) · Cancer · doi:10.1002/cncr.23243 · Cited by 203
Typical medullary breast carcinomas have a basal/myoepithelial phenotype
Jacquemier, J., Padovani, L., Rabayrol, L., Lakhani, S. R., Penault‐Llorca, F., Denoux, Y., Fiche, M., Figueiro, P., Maisongrosse, V., Ledoussal, V., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1845 · Cited by 202
Wang, Z. C., Lin, M., Wei, L.-J., Li, C., Miron, A., Lodeiro, G., Harris, L., Ramaswamy, S., Tanenbaum, D. M., Meyerson, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2570 · Cited by 190
Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer
Liedtke, C., Hatzis, C., Symmans, W. F., Desmedt, C., Haibe-Kains, B., Valero, V., Kuerer, H., Hortobagyi, G. N., Piccart-Gebhart, M., Sotiriou, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5934 · Cited by 187
Self-citationCrook, T., Brooks, L. A., Crossland, S., Osin, P., Barker, K. T., Waller, J., Philp, E., Smith, P. D., Yulug, I., Peto, J., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1202106 · Cited by 179
Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer
Troester, M. A., Hoadley, K. A., Sørlie, T., Herbert, B.-S., Børresen-Dale, A.-L., Lønning, P. E., Shay, J. W., Kaufmann, W. K., & Perou, C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0107 · Cited by 179
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
Tutt, A., Robson, M., Garber, J. E., Domchek, S., Audeh, M. W., Weitzel, J. N., Friedlander, M., & Carmichael, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra501 · Cited by 174
Survival among women with triple receptor-negative breast cancer and brain metastases
Dawood, S., Broglio, K., Esteva, F. J., Yang, W., Kau, S.-W., Islam, R., Albarracin, C., Yu, T. K., Green, M., Hortobagyi, G. N., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn682 · Cited by 165
Carey, L. A., Rugo, H. S., Marcom, P. K., Irvin, W., Ferraro, M., Burrows, E., He, X., Perou, C. M., & Winer, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1009 · Cited by 163
Chabalier, C., Lamare, C., Racca, C., Privat, M., Valette, A., & Larminat, F. (2006) · Cell Cycle · doi:10.4161/cc.5.9.2726 · Cited by 159
Yang, W. T., Dryden, M. J., Broglio, K. R., Gilcrease, M. Z., Dawood, S. S., Dempsey, P. J., Valero, V., Hortobágyi, G. N., Atchley, D. P., & Arun, B. K. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9810-6 · Cited by 157
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer: Table 1
Chappuis, P. O., Goffin, J., Wong, N., Perret, C., Ghadirian, P., Tonin, P. N., & Foulkes, W. D. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.8.608 · Cited by 156
Freedman, G. M., Anderson, P. R., Li, T., & Nicolaou, N. (2009) · Cancer · doi:10.1002/cncr.24094 · Cited by 155
Survival in patients with brain metastases from breast cancer
Eichler, A. F., Kuter, I., Ryan, P. D., et al. (2008) · Cancer · doi:10.1002/cncr.23468 · Cited by 154
Harris, L. N., Broadwater, G., Lin, N., Miron, A., Schnitt, S. J., Cowan, D., Lara, J. F., Bleiweiss, I. J., Berry, D. A., Ellis, M. J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1622 · Cited by 154
Rodríguez-Pinilla, S. M., Honrado, E., Hardisson, D., Benitez, J. J., & Palacios, J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9184-1 · Cited by 135
Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers
Nofech‐Mozes, S., Trudeau, M., Kahn, H. K., Dent, R. A., Rawlinson, E., Sun, P., Narod, S. A., & Hanna, W. M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0295-8 · Cited by 116
Tommiska, J., Bártková, J., Heinonen, M., Hautala, L. C., Kilpivaara, O., Eerola, H., Aittomäki, K., Hofstetter, B., Lukáš, J., von Smitten, K., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210885 · Cited by 116
Impact of Triple Negative Phenotype on Breast Cancer Prognosis
Kaplan, H. G., & Malmgren, J. A. (2008) · The Breast Journal · doi:10.1111/j.1524-4741.2008.00622.x · Cited by 110
Kriege, M., Seynaeve, C., Meijers-Heijboer, H. E. J., Collee, M. J., Menke‐Pluymers, M. B. E., Bartels, C. C. M., Tilanus‐Linthorst, M. M. A., Blom, J., Huijskens, E., Jager, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9067 · Cited by 104
Gluz, O., Nitz, U. A., Harbeck, N., Ting, E., Kates, R. E., Herr, A., Lindemann, W., Jackisch, C., Berdel, W. E., Kirchner, H. H., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm551 · Cited by 103
Self-citationO’Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D. A., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B. M., & Bradley, C. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.3 · Cited by 95
Frasci, G., Comella, P., Rinaldo, M., Iodice, G., Bonito, M. D., D’Aiuto, M., Petrillo, A., Lastoria, S., Siani, C., Comella, G., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn748 · Cited by 90
Torrisi, R., Balduzzi, A., Ghisini, R., Rocca, A., Bottiglieri, L., Giovanardi, F., Veronesi, P., Luini, A., Orlando, L., Viale, G., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0652-z · Cited by 89
Dairkee, S. H., Puett, L., & Hackett, A. J. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.9.691 · Cited by 85
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
Ryan, P. D., Tung, N., Isakoff, S. J., Golshan, M. A., Richardson, A., Corben, A. D., Smith, B. L., Gelman, R. S., Winer, E. P., & Garber, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.551 · Cited by 82
Collins, L. C., Martyniak, A., Kandel, M., et al. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31819c1c93 · Cited by 81
Uhm, J. E., Park, Y. H., Yi, S. Y., Cho, E. Y., Choi, Y., Lee, S. J., Park, M. J., Lee, S., Jun, H. J., Ahn, J. S., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24090 · Cited by 72
Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.
Finn, R., Bengala, C., Ibrahim, N., Strauss, L., Fairchild, J. P., Sy, O., Roche, H. H., Sparano, J. A., & Goldstein, L. J. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-3118 · Cited by 70
Bidard, F., Matthieu, M.-C., Chollet, P. J. M., Raoefils, I., Abrial, C., Dômont, J., Spielmann, M., Delaloge, S., André, F., & Penault-Llorca, F. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn039 · Cited by 63
Yang, X. R., Pfeiffer, R. M., García‐Closas, M., Rimm, D. L., Lissowska, J., Brinton, L. A., Pepłońska, B., Hewitt, S. M., Cartun, R. W., Mandich, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2142 · Cited by 62
αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer
Ivanov, O., Chen, F., Wiley, E. L., Keswani, A., Diaz, L. K., Memmel, H. C., RADEMAKER, A. W., Gradishar, W. J., Morrow, M., Khan, S. A., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9796-0 · Cited by 61
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Gronwald, J., Byrski, T., Huzarski, T., Dent, R. A., Bielicka, V., Zuziak, D., Wiśniowski, R., Lubiński, J., & Narod, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.502 · Cited by 61
Time to disease recurrence in basal‐type breast cancers: Effects of tumor size and lymph node status
Dent, R. A., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009) · Cancer · doi:10.1002/cncr.24573 · Cited by 59
Moon, H., Han, W., Lee, J. W., Ko, E. S., Kim, E., Yu, J. H., Kang, S. Y., Moon, W. K., Cho, N., Park, I.-A., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn683 · Cited by 59
Gilmore, P. M., McCabe, N., Quinn, J. E., Kennedy, R. D., Gorski, J. J., Andrews, H. N., McWilliams, S., Carty, M., Mullan, P. B., Duprex, W. P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4080 · Cited by 45
Pivot, X. B., Li, R. K., Thomas, E. S., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.07.015 · Cited by 24
Leone, J. P., Guardiola, V., Venkatraman, A., Pegram, M. D., Welsh, C. F., Silva, O., Larrieux, R., Franchesci, D., Gómez, C., & Hurley, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.625 · Cited by 22
Genotypic characterization of phenotypically defined triple-negative breast cancer
Sparano, J. A., Goldestin, L. J., Childs, B. H., Shak, S., Badve, S., Baehner, F. L., Davidson, N. E., Sledge, G. W., & Gray, R. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.500 · Cited by 16
André, F., Dessen, P., Job, B., Delaloge, S., Pusztai, L., & Lazar, V. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.569 · Cited by 7
Self-citationGRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer.
Sparano, J. A., Gray, R. P., Goldstein, L. J., Childs, B. H., Bugarini, R., Rowley, S., Baker, J., Shak, S., Badve, S., Baehner, F. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-25 · Cited by 3
Cited by
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
Denkert, C., Liedtke, C., Tutt, A., & von Minckwitz, G. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32454-0 · Cited by 872
Self-citationRole of epidermal growth factor receptor in breast cancer
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2289-9 · Cited by 806
An overview of triple-negative breast cancer
Kumar, P., & Aggarwal, R. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 771
ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer
van Geldermalsen, M., Wang, Q., Nagarajah, R., Marshall, A. D., Thoeng, A., Gao, D., Ritchie, W., Feng, Y., Bailey, C. G., Deng, N., et al. (2016) · Oncogene · doi:10.1038/onc.2015.381 · Cited by 580
Metadata
- Authors
- Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 20
- Issue
- 12
- Pages
- 1913-1927
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2138474420
- Cited by
- 687
- References
- 131
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.